Medtronic Announces Workforce Reduction Amid Diabetes Business Restructuring and MiniMed IPO

From May 5 to May 9, the company's human resources team held multiple special meetings internally to explain the "Staff Transition Management Guidelines" to relevant business units. Although the specific terms have not been disclosed yet, insiders analyzed that the guidelines might include employee placement plans and communication process regulations.

Starting from this Monday, Medtronic employees have been receiving layoff notice emails.

On May 13, Medtronic's Physiological Research Laboratory in Coon Rapids, Minnesota, was the first to implement staff adjustments. A researcher who wished to remain anonymous confirmed to the media,About 20 employees received dismissal notices that morning., who also received the job adjustment notice in the afternoon.

It is worth noting that,The diabetes business line was the most affected in this adjustment.。According to internal sources, it is speculated that approximately 100 employees in this division will be laid off.The affected positions are extensive, involving multiple departments such as sales, quality assurance (QA), research and development, and technical support. The technical support department in Northridge may be entirely eliminated, with related work expected to be transferred to Manila, Philippines.

In addition to the Diabetes Business Division and the Physiology Research Laboratory, there are indications that layoffs may also occur in other departments of Medtronic.

Medtronic's Corporate Communications Lead, Erika Winkels, responded to this by stating: "It is a necessary measure for companies to continuously assess operational efficiency. We always prioritize employee rights and will implement transitional safeguard measures in accordance with laws and regulations, while providing career development support services." However, the company has not yet disclosed the specific scale of adjustments.

According to industry observations, this structural adjustment focuses on the diabetes business as its core, while changes in other departments fall within the scope of routine business optimization. We will continue to track the subsequent progress of this strategic adjustment.